{"protocolSection": {"identificationModule": {"nctId": "NCT00542269", "orgStudyIdInfo": {"id": "CSPP100AGB01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome", "officialTitle": "A Twelve Week, Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Ramipril/Amlodipine (300/10/5-10 mg) Compared to the Combinations of Ramipril/Amlodipine (10/5-10 mg) and Aliskiren/Amlodipine (300/5-10 mg) in Patients With Essential Hypertension and Metabolic Syndrome Not Adequately Responsive to Amlodipine 5-10 mg", "acronym": "ALTO"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "TERMINATED", "whyStopped": "Early termination of the study due to slow recruitment.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-03"}, "primaryCompletionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-09", "studyFirstSubmitQcDate": "2007-10-10", "studyFirstPostDateStruct": {"date": "2007-10-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-01-06", "resultsFirstSubmitQcDate": "2011-04-26", "resultsFirstPostDateStruct": {"date": "2011-05-24", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-26", "lastUpdatePostDateStruct": {"date": "2011-05-24", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic syndrome who do not respond adequately to amlodipine monotherapy."}, "conditionsModule": {"conditions": ["Hypertension With Metabolic Syndrome"], "keywords": ["Hypertension", "Metabolic Syndrome", "Dual combination therapy", "Triple combination therapy", "Aliskiren", "Direct Renin inhibitor"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 178, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren / ramipril / amlodipine", "type": "EXPERIMENTAL", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "interventionNames": ["Drug: Amlodipine", "Drug: Aliskiren", "Drug: Ramipril"]}, {"label": "Aliskiren / amlodipine", "type": "EXPERIMENTAL", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "interventionNames": ["Drug: Amlodipine", "Drug: Aliskiren"]}, {"label": "Ramipril / amlodipine", "type": "ACTIVE_COMPARATOR", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "interventionNames": ["Drug: Amlodipine", "Drug: Ramipril"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine", "description": "amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "armGroupLabels": ["Aliskiren / amlodipine", "Aliskiren / ramipril / amlodipine", "Ramipril / amlodipine"]}, {"type": "DRUG", "name": "Aliskiren", "description": "aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "armGroupLabels": ["Aliskiren / amlodipine", "Aliskiren / ramipril / amlodipine"]}, {"type": "DRUG", "name": "Ramipril", "description": "ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "armGroupLabels": ["Aliskiren / ramipril / amlodipine", "Ramipril / amlodipine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine)", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msSBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "timeFrame": "Baseline to Week 12"}, {"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msSBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "timeFrame": "Baseline to Week 12"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msDBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "timeFrame": "Baseline to Week 12"}, {"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msDBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "timeFrame": "Baseline to Week 12"}, {"measure": "Percentage of Patients Who Achieved Normalized Blood Pressure at End of Study", "description": "Normalized was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.", "timeFrame": "Week 12"}, {"measure": "Change in HOMA-IR From Baseline to End of Study", "description": "Homeostasis model assessment-insulin resistance (HOMA-IR) was defined as (fasting insulin \\[\u03bcU/mL\\] x fasting glucose \\[mmol/L\\]) / 22.5.", "timeFrame": "Baseline to Week 12"}, {"measure": "Change in HOMA-\u03b2 From Baseline to End of Study", "description": "Homeostasis model assessment-\u03b2 (HOMA-\u03b2) was defined as fasting insulin (\u03bcU/mL) x 20 / (fasting glucose (mmol/L) - 3.5).", "timeFrame": "Baseline to Week 12"}, {"measure": "Change in HbA1c (Glycated Hemoglobin) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine", "timeFrame": "Baseline to Week 12"}, {"measure": "Change in HbA1c (Glycated Hemoglobin) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine)", "timeFrame": "Baseline to Week 12"}, {"measure": "Percentage of Patients Who Developed Diabetes at End of Study", "description": "A patient had diabetes if fasting plasma glucose \\> 7 mmol/L.", "timeFrame": "Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Outpatients 18-75 years of age.\n* Male or female patients are eligible.\n* Patients with a diagnosis of hypertension:\n* Newly diagnosed patients or patients who have not been treated for hypertension within the 4 weeks prior to Visit 1 must have a mean sitting systolic blood pressure (MSSBP) \\> 150 mmHg and \\< 180 mmHg at Visit 1.\n* Patients treated with antihypertensive monotherapy must have a MSSBP \u2265 140 mmHg and \\<180 mmHg at Visit 1.\n* Patients taking amlodipine monotherapy MSSBP \\> 140 mmHg and \\< 180 mmHg at visit 1.\n* All patients must have a MSSBP \u2265 140 mmHg and \\< 180 mmHg at Visit 3, the end of the amlodipine run-in period.\n* Metabolic syndrome.\n* Patients who are eligible and able to participate in the study, and who consent to do so after the purpose and nature of the investigation has been clearly explained to them (written inform consent form).\n\nExclusion Criteria:\n\n* Severe hypertension (office cuff MSDBP \u2265 115 mmHg and/or MSSBP \u2265 180 mmHg).\n* History or evidence of a secondary form of hypertension.\n* History of hypertensive encephalopathy or cerebrovascular accident, transient ischemic cerebral attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention (PCI).\n* Serum sodium \\< 135 mmol/L at Visit 1 if confirmed on repeat sample.\n* Serum potassium \\< 3.5 mmol/L or \u2265 5.3 mmol/L at Visit 1, if confirmed on repeat sample.\n* Type 1 diabetes mellitus.\n* Type 2 diabetes if oral hypoglycaemic therapy changed (dose change or medication change) in previous 3 months.\n* Pregnant or nursing (lactating) women.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis Great Britian", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Addenbrookes Hospital", "city": "Cambridge", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "FG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "FG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "60"}, {"groupId": "FG002", "numSubjects": "57"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "54"}, {"groupId": "FG002", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "BG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "BG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "57"}, {"groupId": "BG003", "value": "178"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.3", "spread": "8.90"}, {"groupId": "BG001", "value": "58.3", "spread": "8.95"}, {"groupId": "BG002", "value": "59.1", "spread": "8.86"}, {"groupId": "BG003", "value": "59.6", "spread": "8.95"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "126"}]}]}, {"title": "\u2265 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "52"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "54"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "42"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "124"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine)", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msSBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.8", "spread": "1.56"}, {"groupId": "OG001", "value": "-10.9", "spread": "1.59"}]}]}]}, {"type": "PRIMARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msSBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.4", "spread": "1.36"}, {"groupId": "OG001", "value": "-10.0", "spread": "1.39"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msDBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.0", "spread": "0.94"}, {"groupId": "OG001", "value": "-4.1", "spread": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine", "description": "Automated blood pressure determinations were made with the Omron HEM-705CP blood pressure monitor at trough (24 hours \u00b1 3 hours post-dose) and recorded at all study visits following detailed directions specified in the study protocol. Three readings were made and msDBP was calculated as the average of the 3 readings. In the event of aberrant readings, ie, the lowest reading was \u2265 10 mmHg systolic or \u2265 5 mmHg diastolic lower than the highest of the 3 readings, 3 additional readings were obtained. A negative change indicates improvement.", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.8", "spread": "0.98"}, {"groupId": "OG001", "value": "-4.5", "spread": "1.00"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved Normalized Blood Pressure at End of Study", "description": "Normalized was defined as a msSBP \\< 140 mmHg and/or a msDBP \\< 90 mmHg.", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.90"}, {"groupId": "OG001", "value": "43.33"}, {"groupId": "OG002", "value": "42.11"}]}]}]}, {"type": "SECONDARY", "title": "Change in HOMA-IR From Baseline to End of Study", "description": "Homeostasis model assessment-insulin resistance (HOMA-IR) was defined as (fasting insulin \\[\u03bcU/mL\\] x fasting glucose \\[mmol/L\\]) / 22.5.", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.98", "spread": "2.292"}, {"groupId": "OG001", "value": "0.87", "spread": "5.883"}, {"groupId": "OG002", "value": "0.60", "spread": "6.186"}]}]}]}, {"type": "SECONDARY", "title": "Change in HOMA-\u03b2 From Baseline to End of Study", "description": "Homeostasis model assessment-\u03b2 (HOMA-\u03b2) was defined as fasting insulin (\u03bcU/mL) x 20 / (fasting glucose (mmol/L) - 3.5).", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.71", "spread": "152.108"}, {"groupId": "OG001", "value": "0.87", "spread": "5.883"}, {"groupId": "OG002", "value": "0.60", "spread": "6.186"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c (Glycated Hemoglobin) From Baseline to End of Study - Aliskiren/Ramipril/Amlodipine vs Ramipril/Amlodipine", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/mol", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "57"}, {"groupId": "OG001", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.05"}, {"groupId": "OG001", "value": "0.1", "spread": "0.05"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c (Glycated Hemoglobin) From Baseline to End of Study - Aliskiren/Amlodipine vs Ramipril/Amlodipine)", "populationDescription": "Intent-to-treat (ITT) population. All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the variable.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/mol", "timeFrame": "Baseline to Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "54"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.06"}, {"groupId": "OG001", "value": "0.1", "spread": "0.06"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Developed Diabetes at End of Study", "description": "A patient had diabetes if fasting plasma glucose \\> 7 mmol/L.", "populationDescription": "Intent-to-treat (ITT) population: All patients that received at least 1 dose of study drug and had baseline and at least 1 post-baseline assessment of the primary efficacy variable.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}, {"id": "OG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "60"}, {"groupId": "OG002", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.9"}, {"groupId": "OG001", "value": "4.1"}, {"groupId": "OG002", "value": "2.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Aliskiren / Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "seriousNumAffected": 3, "seriousNumAtRisk": 61, "otherNumAffected": 27, "otherNumAtRisk": 61}, {"id": "EG001", "title": "Aliskiren /Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "seriousNumAffected": 1, "seriousNumAtRisk": 60, "otherNumAffected": 24, "otherNumAtRisk": 60}, {"id": "EG002", "title": "Ramipril / Amlodipine", "description": "6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.", "seriousNumAffected": 3, "seriousNumAtRisk": 57, "otherNumAffected": 26, "otherNumAtRisk": 57}], "seriousEvents": [{"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Latex allergy", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Eczema infected", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Glucose tolerance test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 57}]}], "otherEvents": [{"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 16, "numAtRisk": 57}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 57}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 57}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 57}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 57}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 57}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 61}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 57}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000024821", "term": "Metabolic Syndrome"}, {"id": "D000013577", "term": "Syndrome"}], "ancestors": [{"id": "D000004194", "term": "Disease"}, {"id": "D000010335", "term": "Pathologic Processes"}, {"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000007333", "term": "Insulin Resistance"}, {"id": "D000006946", "term": "Hyperinsulinism"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M16355", "name": "Syndrome", "asFound": "Syndrome", "relevance": "HIGH"}, {"id": "M23005", "name": "Metabolic Syndrome", "asFound": "Metabolic Syndrome", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M10370", "name": "Insulin Resistance", "relevance": "LOW"}, {"id": "M9997", "name": "Hyperinsulinism", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000017257", "term": "Ramipril"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}